All News
Filter News
Found 808,592 articles
-
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
3/15/2021
Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene therapy program
-
Oncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)
3/15/2021
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that PEPAXTO® (melphalan flufenamide) is now commercially available and that the first patients are being treated with the drug.
-
Scopus BioPharma Finalizes Arrangements for Submission of IND Package
3/15/2021
Scopus BioPharma Inc. (Nasdaq: "SCPS") today announced the finalization of arrangements for the completion of the investigational new drug ("IND") package for the company's lead drug candidate and its submission to the United States Food and Drug Administration ("FDA").
-
Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy
3/15/2021
- Lead clinical program, an EGFR / TGFβ-trap bifunctional antibody, rapidly enrolling a Phase 1/2 study in leading research hospitals in U.S. and Canada - $40 million in seed financing from global pharmaceutical company Biocon, Ltd. - International R&D team brings strong track record of developing FDA-approved therapies
-
ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations
3/15/2021
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has met the safety requirements for the first 12 participants in its Phase Ib human adenovirus (hAd5)-based T-cell COVID-19 vaccine trials in sublingual and oral formulations
-
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
3/15/2021
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved by the New Jersey Economic Development Authority (NJEDA) to transfer approximately $1.3 million of the total $1.3 million of its available tax benefits to an unrelated,
-
INVO Bioscience Achieves Key Milestone - Signs Agreement to Open First Joint Venture INVOcell Clinic in the United States
3/15/2021
INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the signing of a 50/50 joint venture agreement in partnership with reproductive specialists
-
Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™
3/15/2021
Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™ Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1
-
PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies
3/15/2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA® (deflazacort) following the FDA approval.
-
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
3/15/2021
Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that 50 percent of patients in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin)
-
NCCN Announces New Biosimilars Research Projects in Oncology in Collaboration with Pfizer
3/15/2021
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP), in collaboration with Pfizer Inc., announces ten projects have been chosen to receive funding to support innovative approaches to improve the processes related to appropriate biosimilar adoption in oncology.
-
AVEO Oncology to Regain Ex-North American Rights to AV-203
3/15/2021
AVEO Oncology to Regain Ex-North American Rights to AV-203 - AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 -
-
Intec Pharma and Decoy Biosystems Announce Merger Agreement
3/15/2021
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.
-
CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease
3/15/2021
CuraSen Therapeutics, Inc., a privately held, clinical-stage biotechnology company, announced Phase 1 proof-of-principle data demonstrating that salbutamol, a drug approved to treat respiratory disease, significantly improved brain perfusion as measured by increased cerebral blood flow (CBF) in healthy subjects.
-
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
3/15/2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel.
-
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients
3/15/2021
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID) Targeting safinamide label extension for PD LID in key global markets
-
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
3/15/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference
-
New IPVM Scientific Study Raises Alarm on COVID-19 Temperature Screening Reporting Fevers as Normal
3/15/2021
A new peer-reviewed study by IPVM researchers has found that popular temperature screening devices from 7 different manufacturers systematically manipulate temperature readings, regularly reporting fever-level temperatures as normal.
-
Lygos and the Agile BioFoundry Generate Largest Multi-Omics Dataset to Accelerate Machine Learning Capabilities for Engineering Strains for Producing Organic Acids
3/15/2021
Lygos, Inc., a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it is working with the U.S. Department of Energy Bioenergy Technologies Office’s Agile BioFoundry (ABF) to generate the largest multi-omics dataset for guiding the development of organic acids.
-
Seisa Medical Establishes California Presence With Acquisitions of ProtoQuick and Peridot
3/15/2021
Seisa Medical Inc., a full-service provider of integrated manufacturing and development services to the medical device industry, today announced that it has acquired Bay Area-based businesses ProtoQuick, Inc. and Peridot Corporation.